Altimmune Inc

-0.17 (-1.64%)
Earnings Announcements

Altimmune Announces Q3 2022 Financial Results

Published: 11/10/2022 12:46 GMT
Altimmune Inc (ALT) - Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business Update.
Interim 24-week Readout From Momentum Phase 2 Obesity Trial Expected Q1 2023.
Topline 24-week Data From Phase 1b Trial in Subjects With Non-alcoholic Fatty Liver Disease (nafld) Expected Mid-december 2022.
Altimmune Had Cash, Cash Equivalents and Short-term Investments Totaling $201.9 Million at September 30, 2022.
Qtrly Loss per Share $0.48.
Q3 Earnings per Share View $-0.51 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0.03 Million
Adjusted EPS is expected to be -$0.50

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.55

More details on our Analysts Page.